Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Company Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $1.75 to $1.81
• 50-Day Range: $1.01 to $2.91
• 52-Week Range: $0.81 to $3.02
• Volume: 666,550 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $48.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Iterum Therapeutics Stock Analysis - MarketRank™

Iterum Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 680th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Iterum Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Iterum Therapeutics are expected to grow in the coming year, from ($1.19) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iterum Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iterum Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.47% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iterum Therapeutics does not currently pay a dividend.

Dividend Growth

Iterum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.47% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: N/A

News Sentiment

Iterum Therapeutics has a news sentiment score of -0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

Search Interest

Only 8 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

MarketBeat Follows

2 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of Iterum Therapeutics is held by insiders.

Percentage Held by Institutions

Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

ITRM Stock Analysis - Frequently Asked Questions

How have ITRM shares performed this year?

Iterum Therapeutics' stock was trading at $1.97 at the start of the year. Since then, ITRM stock has decreased by 10.2% and is now trading at $1.77.
View the best growth stocks for 2024 here.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.80 by $1.50.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' top institutional shareholders include XTX Topco Ltd (0.15%). Insiders that own company stock include Michael W Dunne, Corey N Fishman, Brenton Karl Ahrens, Sailaja Puttagunta and Judith M Matthews.
View institutional ownership trends.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Video Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Therapeutics (ATOS).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITRM
• CUSIP: N/A
• CIK: 1659323
• Web: www.iterumtx.com
• Phone: (531) 669-4820
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +182.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,370,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -160.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.48) per share
• Price / Book: -3.69

Miscellaneous

• Outstanding Shares: 27,516,000
• Free Float: 24,985,000
• Market Cap: $48.70 million
• Optionable: Not Optionable
• Beta: 2.40